BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cho SF, Anderson KC, Tai YT. BCMA CAR T-cell therapy arrives for multiple myeloma: a reality. Ann Transl Med 2018;6:S93. [PMID: 30740414 DOI: 10.21037/atm.2018.11.14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Liang H, Ye L, Liang W, Wang R, Ge F, Fan L, Zhu Y, Li GS, Wang SD, Phan K, Sihoe A, Zhang K, He J. Potential factors of specialists' willingness to write editorial and commentary: a retrospective study based on 5,091 invitations. Ann Transl Med 2019;7:805. [PMID: 32042821 DOI: 10.21037/atm.2019.12.75] [Reference Citation Analysis]
2 Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020;34:985-1005. [PMID: 32055000 DOI: 10.1038/s41375-020-0734-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 36.0] [Reference Citation Analysis]
3 Catuogno S, Di Martino MT, Nuzzo S, Esposito CL, Tassone P, de Franciscis V. An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery. Mol Ther Nucleic Acids 2019;18:981-90. [PMID: 31778956 DOI: 10.1016/j.omtn.2019.10.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
4 Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, Yuan J, Wang X, Wang Y, Deng Q. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. Front Immunol 2021;12:720571. [PMID: 34421924 DOI: 10.3389/fimmu.2021.720571] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Beauvais D, Danhof S, Hayden PJ, Einsele H, Yakoub-agha I. Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma. Current Opinion in Oncology 2020;32:418-26. [DOI: 10.1097/cco.0000000000000667] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chari A, Vogl DT, Jagannath S, Jasielec J, Unger TJ, Decastro A, Shah J, Kauffman M, Shacham S, Jakubowiak A. Selinexor‐based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol 2020;189. [DOI: 10.1111/bjh.16550] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]